Medi-Caps Limited announced that Mr. Hemant Sethi has resigned from the position of Chief Financial Officer and Key Managerial Personnel (KMP) effective the close of business hours on June 6, 2026. The resignation was tendered via a letter dated June 3, 2026, and was submitted to pursue career growth and professional opportunities. Mr. Sethi confirmed that there are no other material reasons for his departure beyond those stated.

Consequently, Mr. Sethi ceased to be the KMP authorized to determine the materiality of events or information and to make disclosures to stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board of Directors will place the resignation letter before an upcoming Board meeting for consideration and formal acceptance in accordance with regulations.

The company expressed its appreciation for the valuable services rendered by Mr. Sethi during his tenure. The disclosure was made in compliance with Regulation 30 read with Schedule III of the SEBI Listing Regulations and subsequent circulars issued by the Securities and Exchange Board of India (SEBI).

Resignation Details

The following table outlines the key particulars regarding the change in the company's leadership:

The information was submitted to BSE Limited by Abhishek Jain, Company Secretary and Compliance Officer for Medi-Caps Limited.

Medi-Caps Limited has announced its audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The Board of Directors, meeting on May 21, 2026, approved the results along with the re-appointment of Praveen Shrivastava & Company, Chartered Accountants, as the internal auditor for the financial year 2026-27. The statutory auditors, Rawka & Associates, provided an unmodified opinion on the annual audited financial results.

Financial Performance Overview

For the financial year ended March 31, 2026, the company reported a consolidated net loss of Rs 303.75 lacs, compared to a loss of Rs 57.10 lacs in the previous year. On a standalone basis, the net loss for the year was Rs 13.87 lacs, a decline from the net profit of Rs 55.51 lacs reported in FY25. The company attributed the consolidated loss to unstable political conditions in its major market, the USA, and the standalone loss to volatile market conditions in the real estate sector.

The table below summarizes the key financial metrics for the standalone and consolidated results for the year ended March 31, 2026:

Quarterly Performance

For the quarter ended March 31, 2026, the standalone revenue from operations stood at Rs 53.35 lacs, compared to Rs 89.08 lacs in the corresponding quarter of the previous year. The standalone net loss after tax for the quarter was Rs 31.29 lacs, against a net profit of Rs 70.61 lacs in the same quarter last year. On a consolidated basis, revenue from operations for the quarter was Rs 344.94 lacs, compared to Rs 696.35 lacs in the prior year quarter. The consolidated net profit after tax for the quarter stood at Rs 304.18 lacs, compared to Rs 171.84 lacs in the corresponding quarter of the previous year.

The table below presents the quarterly financial highlights:

Operational Highlights

Revenue from operations on a consolidated basis stood at Rs 1244.85 lacs for FY26, down from Rs 2547.71 lacs in the previous year. The Pharma Division reported a segment revenue of Rs 1014.26 lacs, while the Real Estate Division contributed Rs 230.59 lacs. The Pharma Division incurred a segment loss of Rs 288.58 lacs before tax and interest, whereas the Real Estate Division reported a loss of Rs 12.46 lacs for the year.

The company's total consolidated assets as of March 31, 2026, were Rs 11546.42 lacs, comprising non-current assets of Rs 6844.00 lacs and current assets of Rs 4702.42 lacs. The total equity and liabilities stood at Rs 11546.42 lacs, with equity of Rs 11161.18 lacs and liabilities of Rs 385.24 lacs. The full format of the audited financial results is available on the BSE website at www.bseindia.com and on the company's website at www.medicaps.com .